The 2018 annual report and AGM presentation forecast FDA approval in 2019. They haven't submitted yet, but had 'pre-submission dialogue' with the FDA last year and since reported good progress toward submission.
An investor wanting to get the CGT discount upon a sale after FDA approval would therefore want to look at buying soon, but perhaps traders don't aim for this.
In the meantime their sales seem to been increasing nicely and I believe they can already sell in Europe without restriction the enteric kit, with approvals in this region for other products likely this year.
GSS Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)